- 1mg - Anastrozole;
Without a Prescription
Anastrozole is prescribed for:
- the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
- adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole.
Anastrozole recommended dose is one 1 mg tablet taken once a day. For patients with advanced breast cancer, Anastrozole should be
continued until tumor progression.
For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the
ATAC trial Anastrozole was administered for 5 years.
Patients with Hepatic Impairment
Hepatic metabolism accounts for approximately 85% of Anastrozole elimination. Although clearance of Anastrozole was decreased
in patients with cirrhosis due to alcohol abuse, plasma Anastrozole concentrations stayed in the usual range seen in patients
without liver disease. Therefore, no changes in dose are recommended for patients with mild-to-moderate hepatic impairment,
although patients should be monitored for side effects. Anastrozole has not been studied in patients with severe hepatic
Patients with Renal Impairment
No changes in dose are necessary for patients with renal impairment.
Use in the Elderly
No dosage adjustment is necessary.
Anastrozole is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or to any of the excipients.
Blister of 10 tablets.